TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Stanford-led study found that blocking the age-associated protein 15-PGDH restored knee cartilage in older mice and protected mice from arthritis after knee injury. Treated human cartilage samples also began producing cartilage, but the research does not establish that the approach works as a treatment in patients or can replace joint surgery.
A Stanford Medicine-led research team reports that blocking the age-associated protein 15-PGDH restored knee cartilage in older mice and reduced arthritis after knee injuries in mice. The treatment also prompted cartilage production in human tissue samples, but it has not been shown to regenerate cartilage in patients or to prevent the need for joint replacement surgery.
The researchers found that 15-PGDH levels roughly doubled in knee cartilage as mice aged. They treated older animals with a small-molecule inhibitor of the protein and reported that naturally occurring cartilage loss was reversed. In a separate experiment, the treatment protected mice from developing arthritis after knee injuries designed to resemble ACL tears in people. The supplied report does not provide the experiments’ sample sizes, follow-up periods or detailed effect measurements.
The team also tested cartilage collected during human knee replacement operations. According to the report, samples exposed to the inhibitor began producing new, functional cartilage. These were laboratory tissue samples, not people receiving the drug. The distinction matters: the results offer evidence relevant to human biology, but they do not show that a medicine can restore cartilage or relieve symptoms in patients.
The study appeared in the journal Science. Senior authors Helen Blau, a professor of microbiology and immunology, and Nidhi Bhutani, an associate professor of orthopaedic surgery, led the work. The researchers investigated whether inhibiting 15-PGDH could address cartilage damage associated with aging and injury, rather than only treating pain or other symptoms.
A Possible Route Beyond Symptom Relief
Osteoarthritis can cause pain, swelling and reduced movement as joint cartilage wears down. The source report estimates that the condition affects about one in five U.S. adults and accounts for roughly $65 billion in direct health care costs each year. Current care mainly manages symptoms; for severe disease, joint replacement may be considered. The study points to a possible strategy aimed at cartilage loss itself.
If future research shows that the approach is safe and effective in people, it could inform treatments delivered as a pill or injection. That possibility is a prospect, not an available therapy: the mouse findings and laboratory results do not establish that patients could avoid knee or hip replacement. The work matters because it suggests adult cartilage may retain more capacity for repair than commonly assumed, and because it identifies a potential biological target for further study.
knee cartilage regeneration supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Researchers Targeted 15-PGDH
Articular cartilage is the smooth tissue covering the ends of bones in joints. It has limited natural repair capacity. In osteoarthritis, cartilage cells called chondrocytes can produce inflammatory molecules and break down collagen, a structural protein that helps cartilage withstand forces. As the tissue thins and softens, joints can become painful and difficult to move.
15-PGDH breaks down prostaglandin E2, a molecule involved in tissue function. The Stanford group had previously studied 15-PGDH as a protein whose abundance rises with age and whose inhibition had supported regeneration in other tissues in animal research. In this study, the researchers examined whether the same pathway affected cartilage. Rather than finding that repair depended on a new population of stem cells, they observed existing chondrocytes changing their gene activity toward a more youthful pattern, according to the report.
“This is a new way of regenerating adult tissue, and it has significant clinical promise for treating arthritis due to aging or injury.”
— Helen Blau, Stanford professor of microbiology and immunology
As an affiliate, we earn on qualifying purchases.
Patient Benefits Remain Unproven
The results described are from mice and human tissue samples, not a clinical trial. The supplied source does not say whether the inhibitor has been tested for safety or effectiveness in people, what dose might be appropriate, or how long any repair would last. It also does not establish whether treatment could restore cartilage sufficiently to improve pain, movement or other patient outcomes.
It remains unclear whether the approach could work across different forms and stages of osteoarthritis, or whether an oral medicine or injection could reach the relevant joint tissue safely. The headline question of whether joint replacements could be avoided is therefore not answered by this study. The report describes a possible future application, not a replacement for current medical care.
joint health supplements for aging
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Evidence Needed Before Patient Use
The next key step would be further research establishing how the inhibitor works, how it should be delivered, and whether it can be used safely. If those studies support moving forward, clinical trials would need to test the treatment in people and measure outcomes such as cartilage condition, pain, mobility and adverse effects. The supplied report does not give a clinical-trial timetable or say that trials have begun.
For now, the finding is a preclinical research advance. Whether 15-PGDH inhibition can become a treatment that changes osteoarthritis care—or affects demand for joint replacement—will depend on evidence from human studies that has not yet been reported.
As an affiliate, we earn on qualifying purchases.
Key Questions
Did the researchers regrow cartilage in people?
No. The report says treated human cartilage samples began producing cartilage in laboratory testing. It does not report that patients received the treatment or regenerated cartilage in their bodies.
What is 15-PGDH?
15-PGDH is a protein that breaks down prostaglandin E2. The study found that its levels rose with age in mouse knee cartilage and tested whether blocking it could support cartilage repair.
Could this treatment prevent knee or hip replacement?
That is not known. The researchers suggest the approach might eventually reduce the need for replacement surgery if it works in people, but the reported evidence comes from mice and human tissue samples.
Is a 15-PGDH inhibitor available for osteoarthritis?
The report does not describe an approved or available osteoarthritis medicine based on this research. It also does not say that human clinical trials have begun.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
